PE20220134A1 - Compuestos de pirrolidina - Google Patents
Compuestos de pirrolidinaInfo
- Publication number
- PE20220134A1 PE20220134A1 PE2021002037A PE2021002037A PE20220134A1 PE 20220134 A1 PE20220134 A1 PE 20220134A1 PE 2021002037 A PE2021002037 A PE 2021002037A PE 2021002037 A PE2021002037 A PE 2021002037A PE 20220134 A1 PE20220134 A1 PE 20220134A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- compound
- pyrrolidine compounds
- nhso2nh
- ch2nhch2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Referida a un compuesto derivado de pirrolidina de formula (I), donde L se selecciona del grupo que consiste en -CH2NHCH2-, -CH2NH-, - NH-, -S-, -S(O)-, -S(O)2-, -O-, -OCH2-, -OCH2CH2O-, -NHSO2NH-, formula (II), formula (III), y; R1, R2, R3, R4, R5 y R6 son H y CH3. Un compuesto preferido es un compuesto de formula (IV). Tambien esta referida a una composicion farmaceutica. Dichos compuestos reducen los niveles de lipoproteina a y son utiles en el tratamiento de enfermedades cardiovasculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382477 | 2019-06-07 | ||
| PCT/US2020/035825 WO2020247429A1 (en) | 2019-06-07 | 2020-06-03 | Pyrrolidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220134A1 true PE20220134A1 (es) | 2022-01-27 |
Family
ID=66821161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021002037A PE20220134A1 (es) | 2019-06-07 | 2020-06-03 | Compuestos de pirrolidina |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11286249B2 (es) |
| EP (1) | EP3980409A1 (es) |
| JP (4) | JP6940717B2 (es) |
| KR (3) | KR102720992B1 (es) |
| CN (1) | CN114008021B (es) |
| AU (1) | AU2020287599B2 (es) |
| BR (1) | BR112021023347A2 (es) |
| CL (1) | CL2021003202A1 (es) |
| CO (1) | CO2021016295A2 (es) |
| CR (1) | CR20210602A (es) |
| DO (1) | DOP2021000254A (es) |
| EA (1) | EA202193007A1 (es) |
| EC (1) | ECSP21088515A (es) |
| IL (2) | IL321703A (es) |
| JO (1) | JOP20210319A1 (es) |
| MA (1) | MA56115A (es) |
| MX (2) | MX2021014913A (es) |
| MY (1) | MY200810A (es) |
| PE (1) | PE20220134A1 (es) |
| PH (1) | PH12021553062A1 (es) |
| SA (1) | SA521431048B1 (es) |
| SG (1) | SG11202113244UA (es) |
| UA (1) | UA128540C2 (es) |
| WO (1) | WO2020247429A1 (es) |
| ZA (1) | ZA202109251B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202334116A (zh) | 2021-11-03 | 2023-09-01 | 大陸商上海拓界生物醫藥科技有限公司 | 一種取代的苯丙酸衍生物及其用途 |
| JP7792010B2 (ja) * | 2022-01-26 | 2025-12-24 | イーライ リリー アンド カンパニー | ピロリジン化合物 |
| KR20250164752A (ko) * | 2023-03-24 | 2025-11-25 | 상하이 징신 바이오메디컬 컴퍼니, 리미티드 | 고리형 아민 유도체 및 그 조성물과 응용 |
| WO2024217537A1 (zh) * | 2023-04-21 | 2024-10-24 | 深圳信立泰药业股份有限公司 | 一种叔胺类化合物及其制备方法和医药用途 |
| WO2024230805A1 (zh) * | 2023-05-11 | 2024-11-14 | 江苏恒瑞医药股份有限公司 | 一种脂蛋白化合物晶型及其制备方法 |
| CN120035578A (zh) * | 2023-05-19 | 2025-05-23 | 深圳信立泰药业股份有限公司 | 一种磺酰胺类化合物及其制备方法和医药用途 |
| AU2024308276A1 (en) | 2023-06-30 | 2025-11-13 | Eli Lilly And Company | Therapeutic uses and doses of lp(a) disrupter compounds |
| AU2024298640A1 (en) | 2023-07-21 | 2026-01-22 | Eli Lilly And Company | Piperidine Compounds with Lp(a) Lowering Activity |
| AU2024301240A1 (en) | 2023-07-21 | 2026-01-22 | Eli Lilly And Company | PYRROLIDINE COMPOUNDS Lp(a) LOWERING ACTIVITY |
| WO2025024218A1 (en) | 2023-07-21 | 2025-01-30 | Eli Lilly And Company | PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY |
| AU2024301644A1 (en) | 2023-07-21 | 2026-01-22 | Eli Lilly And Company | Piperidine, morpholine and tetrahydro-pyridazine compounds with lp(a) lowering activity |
| CN119490445A (zh) * | 2023-08-15 | 2025-02-21 | 深圳信立泰药业股份有限公司 | 一种酰基类化合物及其制备方法和医药用途 |
| WO2025103442A1 (zh) * | 2023-11-17 | 2025-05-22 | 上海翊石医药科技有限公司 | 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途 |
| WO2025108255A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海齐鲁制药研究中心有限公司 | 一种多环类衍生物、其制备方法和应用 |
| WO2025237188A1 (zh) * | 2024-05-14 | 2025-11-20 | 石家庄以岭药业股份有限公司 | 一种LP(a)抑制剂化合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2685325B1 (fr) * | 1991-12-20 | 1994-02-04 | Adir Cie | Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| WO2003016265A1 (en) * | 2001-08-17 | 2003-02-27 | Eisai Co., Ltd. | Cyclic compound and ppar agonist |
| WO2005068410A1 (en) | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| JP2007525408A (ja) * | 2003-12-24 | 2007-09-06 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロール管理および関連使用のためのケトン化合物および組成物 |
| BRPI0813837A2 (pt) | 2007-07-27 | 2015-01-06 | Hoffmann La Roche | 2-azetidinametanoaminas e 2-pirrolidinametanoaminas como ligantes de taar |
| US10815197B2 (en) | 2016-02-03 | 2020-10-27 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | N-sulfonyl benzamides as voltage-gated sodium channel inhibitors |
| CN112321475B (zh) | 2020-11-13 | 2022-06-10 | 四川大学 | 一种γ-氨基酸类似物及其合成方法 |
-
2020
- 2020-06-03 CN CN202080041924.XA patent/CN114008021B/zh active Active
- 2020-06-03 MY MYPI2021007256A patent/MY200810A/en unknown
- 2020-06-03 MA MA056115A patent/MA56115A/fr unknown
- 2020-06-03 EA EA202193007A patent/EA202193007A1/ru unknown
- 2020-06-03 PH PH1/2021/553062A patent/PH12021553062A1/en unknown
- 2020-06-03 JP JP2021505713A patent/JP6940717B2/ja active Active
- 2020-06-03 US US17/056,144 patent/US11286249B2/en active Active
- 2020-06-03 IL IL321703A patent/IL321703A/en unknown
- 2020-06-03 CR CR20210602A patent/CR20210602A/es unknown
- 2020-06-03 UA UAA202106553A patent/UA128540C2/uk unknown
- 2020-06-03 EP EP20747210.1A patent/EP3980409A1/en active Pending
- 2020-06-03 KR KR1020247002433A patent/KR102720992B1/ko active Active
- 2020-06-03 KR KR1020227043106A patent/KR102629923B1/ko active Active
- 2020-06-03 PE PE2021002037A patent/PE20220134A1/es unknown
- 2020-06-03 BR BR112021023347A patent/BR112021023347A2/pt unknown
- 2020-06-03 KR KR1020217040065A patent/KR102477481B1/ko active Active
- 2020-06-03 MX MX2021014913A patent/MX2021014913A/es unknown
- 2020-06-03 SG SG11202113244UA patent/SG11202113244UA/en unknown
- 2020-06-03 WO PCT/US2020/035825 patent/WO2020247429A1/en not_active Ceased
- 2020-06-03 AU AU2020287599A patent/AU2020287599B2/en active Active
- 2020-06-03 JO JOP/2021/0319A patent/JOP20210319A1/ar unknown
-
2021
- 2021-09-02 JP JP2021143227A patent/JP7508422B2/ja active Active
- 2021-11-16 IL IL288174A patent/IL288174B2/en unknown
- 2021-11-18 ZA ZA2021/09251A patent/ZA202109251B/en unknown
- 2021-11-30 CO CONC2021/0016295A patent/CO2021016295A2/es unknown
- 2021-12-01 CL CL2021003202A patent/CL2021003202A1/es unknown
- 2021-12-03 MX MX2025001789A patent/MX2025001789A/es unknown
- 2021-12-07 DO DO2021000254A patent/DOP2021000254A/es unknown
- 2021-12-07 EC ECSENADI202188515A patent/ECSP21088515A/es unknown
- 2021-12-07 SA SA521431048A patent/SA521431048B1/ar unknown
-
2022
- 2022-02-15 US US17/671,806 patent/US12441714B2/en active Active
-
2024
- 2024-06-18 JP JP2024098153A patent/JP7658014B2/ja active Active
-
2025
- 2025-03-26 JP JP2025052039A patent/JP2025098178A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220134A1 (es) | Compuestos de pirrolidina | |
| CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| PE20210004A1 (es) | Inhibidores de mcl-1 | |
| CO2020011852A2 (es) | Inhibidores de canales receptores de potencial transitorio de oxadiazol | |
| CO2019003482A2 (es) | Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética | |
| ECSP11010880A (es) | Compuestos orgánicos | |
| PE20070798A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| CL2022000802A1 (es) | Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3 | |
| UY28695A1 (es) | Derivados de difenilazetidona | |
| CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
| SV2010003459A (es) | Derivados de pirimidina 934 | |
| CL2020002157A1 (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
| MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| DOP2017000188A (es) | Compuestos de benzoxaborol 4-sustituidos y uso de los mismos | |
| ECSP23089582A (es) | Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3 | |
| PE20200848A1 (es) | Compuestos derivados de fenilpiridina con actividad dual anti-btk y anti-itk y composiciones farmaceuticas que los contienen | |
| ECSP21011232A (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |